RINGSIDE part B
110 evidence topics · 25 sources
Objective
Part B primary objective: effect on disease progression
Part B secondary objectives: tumor response, quality of life, and safety
Efficacy, safety, and tolerability compared with placebo
Location and study date
Global conduct and completion of enrollment
Registry status and dates for the combined Part A, Part B, and open-label extension record
| Study characteristic | Quoted record |
|---|---|
| Overall status | “Active, not recruiting” |
| Study start (actual) | “2021-09-01” |
| Primary completion (actual) | “2025-12-03” |
| Study completion (estimated) | “2026-12” |
| Number of locations | “This study has 53 locations” |
Registry sites by country
European Union member states, start of trial, and end of recruitment
Study design
Double-blind, placebo-controlled, randomized phase 3 design with central imaging review
Registry design record
| Study characteristic | Quoted record |
|---|---|
| Official title | “RINGSIDE: A Phase 2/3, Randomized, Multicenter Study to Evaluate AL102 in Patients With Progressing Desmoid Tumors” |
| Study type | “Interventional” |
| Allocation | “Randomized” |
| Interventional model | “Parallel Assignment” |
| Masking | “Quadruple” |
| Protocol number | “AL-DES-01” |
| EU trial number | “2024-515909-26-00” |
Relationship between Part A dose finding and Part B
Eligibility criteria
Key eligibility criteria as presented for the primary analysis
Part B inclusion criteria in the registry record
Additional Part B inclusion criteria in the EU trial record
Exclusion criteria for Parts A and B in the registry record
Additional Part B exclusion criteria in the EU trial record
Open-label extension entry criteria
Treatment
Randomized treatment arms
| Arm | Quoted registry description |
|---|---|
| Part B AL102 | “AL102, recommended dose regimen from Part A, 1.2 mg daily” |
| Part B placebo | “Placebo to match recommended dose regimen from Part A” |
| Open-label extension | “AL102, recommended dose regimen from Part A, 1.2 mg daily” |
| Study drug | “AL102 is an inhibitor of gamma secretase-mediated Notch signaling.” |
Dose levels used for dose reduction
Prohibited prior desmoid tumor therapy before the first dose
Study outcomes
Rationale for using progression-free survival as the primary endpoint
Primary endpoint: progression-free survival by blinded independent central review per RECIST v1.1
Primary endpoint in the EU trial record
Design consistent with prior registrational trials
Precedent: progression-free survival as the primary end point of DeFi
“The DeFi (Desmoid Fibromatosis) trial was a phase 3, international, double-blind, randomized, placebo-controlled trial to determine the efficacy and safety of nirogacestat in patients 18 years of age or older with a histologically confirmed diagnosis of progressing desmoid tumors (defined as ≥20% progression according to the Response Evaluation Criteria in Solid Tumors [RECIST], version 1.1, within 12 months before screening).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The primary end point was progression-free survival, defined as the time from randomization until the date of imaging-based or clinical progression or death.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Both imaging-based and clinical progression were confirmed by blinded independent central review.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Precedent: progression-free survival as the major efficacy outcome in the nirogacestat label
Precedent: progression-free survival as the primary end point of the sorafenib phase 3 trial
Variable natural history and the need for a placebo control
“Interpretation of the data is challenging, given the unpredictable natural history of the condition. Desmoid tumors can show rapid growth followed by periods of stabilization, spontaneous regression, or subsequent growth phases.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In a phase 3 trial of sorafenib involving adults with desmoid tumors, progression-free survival was significantly longer with sorafenib than with placebo (P<0.001); however, 20% of the participants in the placebo group had an objective response, a finding that highlights the need for a placebo control in this population.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Limitations of RECIST and progression-free survival in desmoid tumors
“The dimension-based RECIST is currently employed within clinical trials” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Existing clinical trial endpoints such as the Response Evaluation Criteria in Solid Tumors (version 1.1) and progression-free survival are inadequate in capturing treatment efficacy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These surrogate endpoints for overall survival may not be appropriate for a disease with low mortality and importantly fail to capture whether treatments truly improve symptoms and/or affect daily living.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Alpha-controlled key secondary endpoints
Key secondary endpoint: objective response rate by blinded independent central review per RECIST v1.1
Key secondary endpoint: tumor volume at Week 24 by T2-weighted MRI or CT
Rationale for volumetric and T2-weighted MRI assessment
“The retrospective study also highlighted that RECIST may underestimate efficacy and that a better criterion may be magnetic resonance imaging (MRI) T2-weighted signal intensity, an imaging biomarker that signifies a biologic transformation from a cellular tumor to a collagenous scar.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Exploratory imaging end points included a comparison of RECIST measurements with total tumor volume and MRI T2-weighted signal intensity in patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Tumor assessments by blinded independent central review in the primary analysis poster
Key secondary endpoint: GODDESS worst pain intensity at Week 12
GODDESS scoring and administration in RINGSIDE
Rationale for GODDESS as a disease-specific endpoint
“This study was designed to develop a novel clinical trial endpoint by capturing patient-reported outcomes (PROs).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This is the first disease-specific PRO instrument developed for desmoid tumors.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Exploratory patient-reported endpoints: GODDESS symptom scores and PROMIS Physical Function
Other Part B secondary endpoints in the registry record
Part B secondary end points in the EU trial record
Registry secondary outcome measures without Week 24 and Week 12 time points, February 2026, superseded in June 2026
Registry secondary outcome measures with PROMIS, EQ-5D, and Brief Pain Inventory, November 2024, superseded in May 2025
Statistical analysis description
Number of participants (Planned and analyzed)
Participants randomized in Part B
Participants analyzed for progression-free survival
Registry enrollment for the combined record
Part A enrollment within the combined registry record
Planned enrollment in the registry record, November 2024, superseded in May 2025
Description of analysis sets
Intention-to-treat population defined as all participants who received at least one dose
Hazard ratio model stratified by tumor location
Hierarchy of alpha-controlled and non-alpha-controlled endpoints
Patient-reported outcome analyses in the intention-to-treat population with mixed models for repeated measures
Descriptive analysis of RECIST diameters, tumor volume, and T2-weighted signal
Kaplan-Meier estimation of duration of response
Results
Participant disposition
Duration of exposure by arm
Treatment duration and absence of progressive disease with varegacestat
Baseline characteristics
Demographics, tumor characteristics, and prior therapy
| Characteristic, n (%) | Varegacestat (n=79) | Placebo (n=77) |
|---|---|---|
| Median age (range), years | “42.0 (18–66)” | “39.0 (20–69)” |
| Male | “26 (32.9)” | “29 (37.7)” |
| Female | “53 (67.1)” | “48 (62.3)” |
| Premenopausal | “36 (45.6)” | “38 (49.4)” |
| Target tumor location: extra-abdominal | “60 (75.9)” | “49 (63.6)” |
| Target tumor location: intra-abdominal | “19 (24.1)” | “28 (36.4)” |
| Medical history of FAP | “7 (8.9)” | “8 (10.4)” |
| Median target tumor size per RECIST (range), mm | “75.1 (18.0, 244.9)” | “84.8 (21.3, 666.3)” |
| Any prior therapy | “52 (65.8)” | “60 (77.9)” |
| Prior surgery | “24 (30.4)” | “33 (42.9)” |
| Prior radiation therapy | “8 (10.1)” | “12 (15.6)” |
| Prior systemic therapy | “43 (54.4)” | “46 (59.7)” |
| Prior systemic therapies: 0 lines | “36 (45.6)” | “31 (40.3)” |
| Prior systemic therapies: 1 line | “25 (31.6)” | “22 (28.6)” |
| Prior systemic therapies: 2 or more lines | “18 (22.8)” | “24 (31.2)” |
Premenopausal women as a proportion of female participants
| Characteristic | Varegacestat (n=79) | Placebo (n=77) |
|---|---|---|
| Premenopausal, n/N of female participants (%) | “36/53 (67.9)” | “38/48 (79.2)” |
Baseline symptom burden and physical function
Efficacy results
Primary endpoint: progression-free survival
RINGSIDE phase 3 trial outcomes table
| Outcome | VAR (n=79) | PBO (n=77) | HR (95% CI) or Difference; P value |
|---|---|---|---|
| Median PFS (95% CI), radiographic, months | “NE (NE, NE)” | “24.9 (13.8, NE)” | “0.16 (0.07, 0.38); P<0.0001” |
| Confirmed ORR, n (%) | “44 (55.7)” | “7 (9.1)” | “P<0.0001” |
| TV change (cm3) at Week 24, LS mean (SE) | “-109.6 (40.64)” | “122.8 (42.72)” | “-232.4 (57.39); P<0.0001” |
| WPI (pain) change at Week 12, LS mean (SE) | “-2.24 (0.27)” | “0.18 (0.27)” | “-2.42 (0.37); P<0.0001” |
| Median best % change in TV (not alpha-controlled) | “-83.4” | “11.3” |
Progression-free survival events and median, ASCO 2026 presentation
| Arm | No. of patients | No. of events | Median PFS (95% CI) (mo) |
|---|---|---|---|
| Varegacestat | “79” | “7” | “NE (NE, NE)” |
| Placebo | “77” | “29” | “24.87 (13.80, NE)” |
Progression-free survival hazard ratio with confidence limits to three decimal places
Landmark progression-free survival rates at 1 and 2 years
| Arm | 1 Year | 2 Years |
|---|---|---|
| Varegacestat | “94% (95% CI: 85–98%)” | “89% (95% CI: 78–95%)” |
| Placebo | “66% (95% CI: 52–76%)” | “57% (95% CI: 43–69%)” |
Progression-free survival subgroups
Key secondary endpoint: confirmed objective response rate and complete responses
Objective response, time to response, and best overall response
| Outcome | Varegacestat (n=79) | Placebo (n=77) |
|---|---|---|
| Objective response rate, n (%) [95% CI] | “44 (55.7) [44.1, 66.9]” | “7 (9.1) [3.7, 17.8]” |
| Time to objective response (months), median (range) | “8.2 (2.6–28.0)” | “16.7 (8.1–30.2)” |
| Duration of response (months), median (95% CI), Kaplan-Meier estimate | “NE (NE, NE)” | “NE (NE, NE)” |
| Complete response (CR) | “3 (3.8)” | “1 (1.3)” |
| Partial response (PR) | “41 (51.9)” | “6 (7.8)” |
| Stable disease (SD) | “32 (40.5)” | “59 (76.6)” |
| Progressive disease (PD) | “0” | “10 (13.0)” |
| Not available | “3 (3.8)” | “1 (1.3)” |
Key secondary endpoint: change in tumor volume at Week 24
“Varegacestat: -109.6 (40.64)” (opens the source at this quote in a new tab)
“Placebo +122.8 (42.72)” (opens the source at this quote in a new tab)
“Difference: −232.4 (57.39), P<0.0001” (opens the source at this quote in a new tab)
“Least-squares mean (standard error)” (opens the source at this quote in a new tab)
Tumor volume measured by T2-weighted MRI or CT
Median best percent change in tumor volume
T2-weighted MRI signal intensity: descriptive analysis
Health-related quality of life and patient-reported outcomes
Key secondary endpoint: GODDESS worst pain intensity at Week 12
Exploratory PRO endpoints: GODDESS and PROMIS Physical Function 10a
GODDESS DTSS pain domain score: least-squares mean difference by week
| Analysis visit | Varegacestat participants with data | Placebo participants with data | Difference, varegacestat vs placebo |
|---|---|---|---|
| Week 12 | “52” | “55” | “Diff: -2.32” |
| Week 24 | “47” | “43” | “Diff: -2.02” |
| Week 48 | “37” | “27” | “Diff: -2.70” |
GODDESS DTSS TSS-5 symptom score: least-squares mean difference by week
| Analysis visit | Varegacestat participants with data | Placebo participants with data | Difference, varegacestat vs placebo |
|---|---|---|---|
| Week 12 | “52” | “55” | “Diff: -1.46” |
| Week 24 | “47” | “43” | “Diff: -1.43” |
| Week 48 | “37” | “27” | “Diff: -2.09” |
GODDESS TSS-5 symptom score at week 48, ESMO 2026 press release
PROMIS Physical Function 10a T-score: least-squares mean difference by week
| Analysis visit | Varegacestat participants with data | Placebo participants with data | Difference, varegacestat vs placebo |
|---|---|---|---|
| Week 12 | “54” | “60” | “Diff: +3.13” |
| Week 24 | “47” | “45” | “Diff: +5.84” |
| Week 48 | “37” | “26” | “Diff: +6.54” |
PROMIS Physical Function at week 48, ESMO 2026 press release
Safety results
Overall adverse event summary, ASCO 2026 abstract
Adverse events reported in 25% or more of either arm, ASCO 2026 presentation
| Adverse event (MedDRA preferred term), n (%) | Varegacestat any grade | Varegacestat grade 3+ | Placebo any grade | Placebo grade 3+ |
|---|---|---|---|---|
| Any adverse event | “79 (100)” | “45 (57)” | “70 (91)” | “13 (17)” |
| Diarrhea | “65 (82)” | “8 (10.1)” | “21 (27)” | “0” |
| Fatigue | “35 (44)” | “1 (1.3)” | “18 (23)” | “2 (2.6)” |
| Rash | “34 (43)” | “2 (2.5)” | “9 (12)” | “0” |
| Nausea | “28 (35)” | “0” | “20 (26)” | “0” |
| Cough | “27 (34)” | “0” | “4 (5)” | “0” |
| Hypophosphatemia | “27 (34)” | “1 (1.3)” | “2 (3)” | “0” |
| Alopecia | “26 (33)” | “0” | “3 (4)” | “0” |
| Dry mouth | “24 (30)” | “0” | “5 (7)” | “0” |
| Hair color changes | “20 (25)” | “0” | “0” | “0” |
| Pruritus | “20 (25)” | “0” | “4 (5)” | “0” |
| Rash maculo-papular | “20 (25)” | “1 (1.3)” | “1 (1)” | “0” |
Most common treatment-emergent adverse events reported in 20% or more of either arm, ESMO 2026 safety poster
| Adverse event (MedDRA preferred term), n (%) | Varegacestat any grade | Varegacestat grade ≥3 | Placebo any grade | Placebo grade ≥3 |
|---|---|---|---|---|
| Any adverse event | “79 (100)” | “45 (57)” | “70 (91)” | “13 (17)” |
| Diarrhea | “65 (82)” | “8 (10)” | “21 (27)” | “0” |
| Fatigue | “35 (44)” | “1 (1)” | “18 (23)” | “2 (2.6)” |
| Rash | “34 (43)” | “2 (3)” | “9 (12)” | “0” |
| Nausea | “28 (35)” | “0” | “20 (26)” | “0” |
| Cough | “27 (34)” | “0” | “4 (5)” | “0” |
| Hypophosphatemia | “27 (34)” | “1 (1)” | “2 (3)” | “0” |
| Alopecia | “26 (33)” | “0” | “3 (4)” | “0” |
| Dry mouth | “24 (30)” | “0” | “5 (7)” | “0” |
| Hair color changes | “20 (25)” | “0” | “0” | “0” |
| Pruritus | “20 (25)” | “0” | “4 (5)” | “0” |
| Rash maculo-papular | “20 (25)” | “1 (1)” | “1 (1)” | “0” |
| ALT increase | “18 (23)” | “3 (4)” | “4 (5)” | “0” |
| AST increase | “18 (23)” | “2 (3)” | “2 (3)” | “0” |
| Amenorrhea | “17 (22)” | “0” | “2 (3)” | “0” |
| Upper respiratory tract infection | “17 (22)” | “0” | “5 (7)” | “0” |
| Vomiting | “16 (20)” | “0” | “6 (8)” | “0” |
Frequently reported adverse events as grouped terms, with median time to first onset
| Adverse event, n (%) | Varegacestat all grades | Varegacestat median time to onset (days) | Varegacestat grade ≥3 | Placebo all grades | Placebo median time to onset (days) | Placebo grade ≥3 |
|---|---|---|---|---|---|---|
| Diarrhea | “65 (82.3)” | “14.0” | “8 (10.1)” | “21 (27.3)” | “21.0” | “0” |
| Rash (grouped term) | “56 (70.9)” | “24.0” | “4 (5.1)” | “13 (16.9)” | “69.0” | “0” |
| Fatigue (grouped term) | “46 (58.2)” | “27.5” | “1 (1.3)” | “24 (31.2)” | “19.0” | “2 (2.6)” |
| Hair follicle AEs (grouped term) | “32 (40.5)” | “59.0” | “2 (2.5)” | “3 (3.9)” | “70.0” | “0” |
| Cough (grouped term) | “31 (39.2)” | “16.0” | “1 (1.3)” | “5 (6.5)” | “198.0” | “0” |
| Nausea | “28 (35.4)” | “8.0” | “0” | “20 (26.0)” | “7.5” | “0” |
| Hypophosphatemia | “27 (34.2)” | “29.0” | “1 (1.3)” | “2 (2.6)” | “49.5” | “0” |
| Upper respiratory infection (grouped term) | “27 (34.2)” | “46.0” | “0” | “6 (7.8)” | “136.5” | “0” |
| Dry mouth | “24 (30.4)” | “13.0” | “0” | “5 (6.5)” | “8.0” | “0” |
| Hair color changes | “20 (25.3)” | “60.5” | “0” | “0” | “0” | |
| Ovarian toxicity (grouped term; percentage of the whole population) | “20 (25.3)” | “56.5” | “0” | “2 (2.6)” | “41.5” | “0” |
Select adverse events of interest by grade, including squamous cell carcinoma and keratoacanthoma
| Adverse event of interest | Varegacestat grade 1 | Varegacestat grade 2 | Varegacestat grade 3 | Placebo grade 1 | Placebo grade 2 | Placebo grade 3 |
|---|---|---|---|---|---|---|
| Diarrhea | “43.0%” | “29.1%” | “10.1%” | “23.4%” | “3.9%” | |
| Rash (grouped terms) | “36.7%” | “29.1%” | “5.1%” | “14.3%” | “2.6%” | |
| Ovarian toxicity | “25.3%” | “2.6%” | ||||
| Squamous cell carcinoma and keratoacanthoma | “1.3%” | “6.3%” | “1.3%” | “1.3%” | ||
| Elevated liver enzymes (ALT or AST grade 2 or higher) | “3.8%” | “3.8%” | “2.6%” |
Serious adverse events and deaths
Alopecia by grade
Dose levels and time to first dose reduction or interruption
“1.2 mg once daily” (opens the source at this quote in a new tab)
“0.9 mg once daily” (opens the source at this quote in a new tab)
“0.6 mg once daily” (opens the source at this quote in a new tab)
| Measure | Varegacestat | Placebo |
|---|---|---|
| Median time to first dose reduction to 0.9 mg | “to 0.9 mg (n=60): 3.7 (IQR 1.8, 8.3) months” | “to 0.9 mg (n=7): 5.6 (IQR 2.1, 16.1) months” |
| Median time to first dose reduction to 0.6 mg | “to 0.6 mg (n=36): 7.3 (IQR 3.0, 12.5) months” | “to 0.6 mg (n=2): 10.7 (IQR 4.9, 16.6) months” |
| Median time to first dose interruption | “Varegacestat (n=63): 2.5 (IQR 1.0, 5.7) months” | “Placebo (n=29): 3.4 (IQR 1.9, 7.3) months” |
Adverse events leading to dose reduction
Adverse events leading to dose interruption
Adverse events leading to discontinuation
Ovarian toxicity in premenopausal women
“A known class effect of GSI” (opens the source at this quote in a new tab)
“Varegacestat 56% | Placebo 5%” (opens the source at this quote in a new tab)
“Resolved in 55% of those who reported it” (opens the source at this quote in a new tab)
“No discontinuations for ovarian toxicity” (opens the source at this quote in a new tab)
Ovarian toxicity resolution by treatment disposition
“8 off varegacestat, follow-up available” (opens the source at this quote in a new tab)
“OT resolved in 8 (100%)” (opens the source at this quote in a new tab)
“10 ongoing varegacestat” (opens the source at this quote in a new tab)
“OT resolved in 3 (30%)” (opens the source at this quote in a new tab)
“OT unresolved in 7 (70%)” (opens the source at this quote in a new tab)
“2 off study, no follow-up available” (opens the source at this quote in a new tab)
Most common adverse events by arm, rounded to whole percentages
Study limitations
Summary
- Part B results are available only as an ASCO 2026 meeting abstract and oral presentation, ESMO 2026 presentations, and Immunome press releases and investor presentations. The abstract states that it “does not include a full text component”. The ClinicalTrials.gov record (primary completion December 3, 2025; status active, not recruiting) lists no posted results, and no registry protocol or statistical analysis plan is available for comparison with the reported analyses. The study was “sponsored/funded by Immunome and Ayala Pharmaceuticals, Inc.”.
- The comparator is placebo. No trial has compared varegacestat with nirogacestat, the approved gamma secretase inhibitor; Immunome's cross-trial response rate chart states that “no head-to-head clinical trial has been conducted”.
- Crossover to the open-label extension was allowed from either arm at progression, and the open-label extension is ongoing. Median exposure was 20.3 months with varegacestat and 11.1 months with placebo, so cumulative adverse event frequencies are compared over unequal exposure.
- At the October 7, 2025 data cutoff, 7 of 79 varegacestat participants and 29 of 77 placebo participants had a PFS event; median PFS was not estimable and median duration of response was not reached with varegacestat, which limits the precision of the hazard ratio and of the 2-year landmark estimates.
- The ASCO presentation labels a “Post-hoc subgroup analysis to evaluate patients with poor prognosis”; the subgroups shown include age 30 years or younger, CTNNB1 mutation, and baseline tumor size above 10 cm, and the abstract states only that PFS “consistently favored VAR in all subgroups analyzed”.
- Baseline imbalances include intra-abdominal target tumors (24.1% with varegacestat and 36.4% with placebo), any prior therapy (65.8% and 77.9%), and prior surgery (30.4% and 42.9%); the placebo arm's target tumor size range extends to 666.3 mm.
- Dose reductions due to adverse events occurred in 80% of varegacestat participants (to 0.9 mg in 60 and to 0.6 mg in 36), and dose interruptions in 65%. The efficacy results therefore reflect a 1.2 mg starting dose with frequent reduction, and the dose intensity actually delivered has not been reported.
- The symptom, pain domain, and physical function analyses are exploratory, with nominal p values. Completion declined over time: at week 48, pain and symptom data were available for 37 varegacestat and 27 placebo participants, against 52 and 55 at week 12. The PROMIS Physical Function baseline was “redefined post hoc”. Characteristic adverse events (diarrhea in 82% versus 27%, alopecia in 33% versus 4%, hair color changes in 25% versus 0%) may have allowed participants to infer their assignment, which could bias patient-reported outcomes in a double-blind trial.
- Figures differ between sources. The PFS hazard ratio's 95% CI is 0.07 to 0.38 in the abstract and slides and 0.071 to 0.375 in Immunome releases. ORR is 55.7% versus 9.1% in the abstract and slides and 56% versus 9% in releases. Placebo discontinuation due to adverse events is 7% in the abstract, ASCO slides, and safety poster and 6% in the primary results poster. Premenopausal women are 45.6% of the varegacestat arm in one table and 67.9% of its female participants in another. Rash is 43% as a preferred term and 70.9% as a grouped term. Death is reported as “No deaths due to adverse events” in the ESMO safety poster and as “There were no deaths on study” in the investor presentations. Ovarian toxicity resolved in 55% overall but in all 8 participants with follow-up off treatment. Week 48 PROMIS Physical Function is reported as +3.90 versus −3.04 in the ESMO press release, while the presentation, using the redefined baseline, reports a difference of +6.54.